Exclusive Summary

• Vast & Mature Market: As a WHO Essential Medicine recommended in numerous guidelines for globally prevalent infections like RTIs, it addresses a stable and substantial market demand.
• High-Standard Quality Barrier: PIC/S GMP certification ensures quality equivalent to EU standards, facilitating accelerated registration and market access in over 50 member countries (covering Europe, SEA, LATAM, etc.).
• Clear Clinical Positioning: Widely recommended globally as a crucial second-line or alternative therapy for serious infections such as Community-Acquired Pneumonia (CAP) and Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).
• Cost & Supply Advantage: As a mature generic, it offers significant cost advantages over the originator. We provide a stable supply chain combining high quality and price competitiveness, making it an ideal choice to replace existing suppliers.